How ICER’s Evidence Report Fails Migraine Patients
December 5, 2019
The Institute for Clinical and Economic Review says new acute migraine medications aren’t worth their cost. Here’s how the economists got it wrong.
Categorized in: Analysis
The Institute for Clinical and Economic Review says new acute migraine medications aren’t worth their cost. Here’s how the economists got it wrong.
Categorized in: Analysis